- Home
- PHGE vs EKSO Comparison
PHGE vs EKSO Comparison
Compare PHGE & EKSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHGE
- EKSO
- Stock Information
- Founded
- PHGE 2015
- EKSO 2005
- Country
- PHGE Israel
- EKSO United States
- Employees
- PHGE N/A
- EKSO N/A
- Industry
- PHGE Biotechnology: Pharmaceutical Preparations
- EKSO Medical/Dental Instruments
- Sector
- PHGE Health Care
- EKSO Health Care
- Exchange
- PHGE Nasdaq
- EKSO Nasdaq
- Market Cap
- PHGE 11.0M
- EKSO 11.7M
- IPO Year
- PHGE N/A
- EKSO N/A
- Fundamental
- Price
- PHGE $0.44
- EKSO $3.49
- Analyst Decision
- PHGE Strong Buy
- EKSO Strong Buy
- Analyst Count
- PHGE 1
- EKSO 2
- Target Price
- PHGE $15.00
- EKSO $37.50
- AVG Volume (30 Days)
- PHGE 284.6K
- EKSO 265.1K
- Earning Date
- PHGE 08-13-2025
- EKSO 07-28-2025
- Dividend Yield
- PHGE N/A
- EKSO N/A
- EPS Growth
- PHGE N/A
- EKSO N/A
- EPS
- PHGE N/A
- EKSO N/A
- Revenue
- PHGE N/A
- EKSO $17,544,000.00
- Revenue This Year
- PHGE N/A
- EKSO $0.20
- Revenue Next Year
- PHGE N/A
- EKSO $42.29
- P/E Ratio
- PHGE N/A
- EKSO N/A
- Revenue Growth
- PHGE N/A
- EKSO N/A
- 52 Week Low
- PHGE $0.34
- EKSO $2.73
- 52 Week High
- PHGE $3.86
- EKSO $22.95
- Technical
- Relative Strength Index (RSI)
- PHGE 43.34
- EKSO 40.66
- Support Level
- PHGE $0.43
- EKSO $3.00
- Resistance Level
- PHGE $0.48
- EKSO $3.80
- Average True Range (ATR)
- PHGE 0.05
- EKSO 0.37
- MACD
- PHGE 0.00
- EKSO 0.07
- Stochastic Oscillator
- PHGE 58.82
- EKSO 52.05
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).
About EKSO Ekso Bionics Holdings Inc.
Ekso Bionics Holdings Inc designs, develops and sells exoskeleton technology used in healthcare and industrial markets. The wearable exoskeletons are to be worn over clothes and controlled by a trained operator to augment human strength, endurance, and mobility. The company's segments are Enterprise Health and Personal Health. All of the company's operations are held in the United States. The regions the company operates in are the Americas, EMEA, and APAC.